Rodríguez AM, Nava SC, Sánchez PMJ, Rodríguez WFL

Language: Spanish
References: 13
Page: 349-351
PDF size: 223.89 Kb.

The increase in years of life, the increase in chronic degenerative diseases, and the increase in the number of therapeutic resources mean that patients often have treatments with more than five drugs (polypharmacy), especially patients over 65 years of age, which increases the risks of affecting organs due to the effect of the same treatments, especially the kidney, both because of the susceptibility to being injured by some medications and because of the potential toxicity of several substances; it is necessary to keep this situation in mind in patients to whom we prescribe treatments plus medications. The challenge is to generate new information with better evidence to address this problem rationally.

REFERENCES

1. Selech F, Palma D, Garrido P. Epidemiología del uso de medicamentos en el adulto mayor. Rev Med Clin Condes. 2016; 27 (5): 660-670. doi: 10.1016/j,rmclc.206.09.011.

2. Payne RA, Avery AJ. Polypharmacy: one of the greatest prescribing challenges in general practice. Br J Gen Prect. 2011; 61 (583): 83-84. doi: 10.3399/bigpIIX556146.

3. Aoki T, Ikenouse T, Yamamoto Y, Kise M, Fukuma S, Fukuhara S et al. Attributes of primary care in relation to polypharmacy: a multicenter cross-sectional study in Japan. Int J Qual Health Care. 2017; 29 (3): 378-383. doi: 10.1093/intqhc/mzx035.

4. Kim J, Parish AL. Polypharmacy and medication management in older adults. Nurs Clin North Am. 2017; 52 (3): 457-468.

5. Sánchez-Pérez H, Ramírez-Rosillo FJ, Carrillo-Esper R. Polifarmacia en el adulto mayor. Consideraciones en el perioperatorio. Rev Mex Anest. 2022; 45 (1): 40-47.

6. Organización Panamericana de la Salud. La salud de los adultos mayores: una visión compartida (internet). 2da ed. Washington, DC: OPS, 2011: 209-222. Disponible en: https://iris.paho.org/handle/10665.2/51598

7. Muntner P. Longitudinal measurements of renal function. Semi Nephrol. 2009; 29 (6): 650-657.

8. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298 (17): 2038-2047.

9. Kuro-o M. Klotho and aging. Biochim Biophys Acta. 2009; 1790 (10): 1049-1058.

10. Melk A, Ramassar V, Helms LM, Moore R, Rayner D, Salez K et al. Telomere shortening in kidneys with age. J Am Soc. Nephrol. 2000; 11 (3): 444-453.

11. Wang X, Yang C, Jiang J, Hu Y, Hao Y, Dong JY. Polypharmacy, chronic kidney disease, and mortality among older adults: a prospective study of National Health and nutrition examination survey, 1999-2018. Front Public Health. 2023; 11: 1116583. doi: 10.3389/fpubh.2023.1116583.

12. P?nar Kücükdagli. Polypharmacy and Related Factors in Geriatric Outpatients. Eur J Geriatr Gerontol. 2019; 1 (2): 56-60. doi: 10.4274/ejgg.galenos.2019.144.

13. Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J et al. Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis. BMC Geriatr. 2022; 22 (1): 601. doi: 10.1186/s12877-022-03279-x.